로고
About us
Company overview
History
Leadership
Business Strategy
Contact us
Platform Technology
IMBolution Technology
ePENDY Technology
Pipeline
IMB-101
IMB-102
IMB-201
IMB-202
IMB-401/IMB-402
Media Room
Notice
News
Gallery
Careers
Culture
Recruiting Information
언어선택
ENG
KOR
ENG
전체메뉴
About us
Company overview
History
Leadership
Business Strategy
Contact us
Platform Technology
IMBolution Technology
ePENDY Technology
Pipeline
IMB-101
IMB-102
IMB-201
IMB-202
IMB-401/IMB-402
Media Room
Notice
News
Gallery
Careers
Culture
Recruiting Information
News
Innovative Medicines based on
ImmunoModulatory Biologics
Media Room
About us
Platform Technology
Pipeline
Media Room
Careers
News
Notice
News
Gallery
IMBiologics, ‘Bispecific Antibody’ approved for phase 1 in the US, entering the second half of the year.
Date
2023-08-01 13:32:50
View
2000
For more information, please visit :
IMBiologics News
(full article available in Korean)
Prev
IMBiologics successfully closes series B financing round with 20B KRW
Next
金斯瑞蓬勃生物祝贺IMBiologics双抗项目IMB-101获FDA临床试验批...
목록
President(CEO) : Gyongsik Ha
260, Changnyong-daero, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea